Literature DB >> 16001113

Effects of paroxetine on cardiovascular response to mental stress in subjects with a history of coronary artery disease and no psychiatric diagnoses.

Michael Golding1, Michael Kotlyar, Stanley W Carson, Sherri Hoyler, Cindy Lazarus, Colin Davidson, Joseph Guzzo, Eric Sontz, J C Garbutt.   

Abstract

RATIONALE: Paroxetine may decrease mental stress-induced cardiovascular responses and so benefit individuals with heart disease, even those with no psychiatric illness.
OBJECTIVES: The effects of paroxetine on cardiovascular measures during a speech task were evaluated in psychiatrically healthy subjects with a history of coronary artery disease (CAD).
METHODS: Eight subjects completed this double-blind, placebo-controlled, cross-over study in which each subject took 1 month of paroxetine and 4 weeks of placebo in random order. While on each study, medication, blood pressure, heart rate, and plasma norepinephrine concentrations were measured during a period of relaxation and during a mental stressor. The mental stressor consisted of thinking about a stressful topic, speaking about the topic, and listening to a tape-recorded replay of the speech.
RESULTS: While on paroxetine, systolic blood pressure and diastolic blood pressure were 10-15% lower (p < 0.005) during the stressor, relative to measures obtained while on placebo. Pulse and plasma norepinephrine concentrations during stress trended lower during paroxetine treatment but did not reach statistical significance.
CONCLUSION: Paroxetine has antihypertensive properties during periods of psychological stress in psychiatrically healthy subjects with a history of CAD, and so should be evaluated for potential cardio-protective qualities.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16001113     DOI: 10.1007/s00213-005-0075-7

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  23 in total

Review 1.  Systematic review of mental stress-induced myocardial ischaemia.

Authors:  P C Strike; A Steptoe
Journal:  Eur Heart J       Date:  2003-04       Impact factor: 29.983

2.  Fluvoxamine reduces physiologic reactivity to trauma scripts in posttraumatic stress disorder.

Authors:  P Tucker; K L Smith; B Marx; D Jones; R Miranda; J Lensgraf
Journal:  J Clin Psychopharmacol       Date:  2000-06       Impact factor: 3.153

3.  Blood pressure changes during short-term fluoxetine treatment.

Authors:  J D Amsterdam; F Garcia-Espana; J Fawcett; F M Quitkin; F W Reimherr; J F Rosenbaum; C Beasley
Journal:  J Clin Psychopharmacol       Date:  1999-02       Impact factor: 3.153

4.  Prognostic value of mental stress testing in coronary artery disease.

Authors:  D S Krantz; H T Santiago; W J Kop; C N Bairey Merz; A Rozanski; J S Gottdiener
Journal:  Am J Cardiol       Date:  1999-12-01       Impact factor: 2.778

Review 5.  Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions.

Authors:  D J Greenblatt; L L von Moltke; J S Harmatz; R I Shader
Journal:  J Clin Psychopharmacol       Date:  1999-10       Impact factor: 3.153

6.  The 'Trier Social Stress Test'--a tool for investigating psychobiological stress responses in a laboratory setting.

Authors:  C Kirschbaum; K M Pirke; D H Hellhammer
Journal:  Neuropsychobiology       Date:  1993       Impact factor: 2.328

7.  Central neurochemical factors related to serotonin metabolism and cardiac ventricular vulnerability for repetitive electrical activity.

Authors:  S H Rabinowitz; B Lown
Journal:  Am J Cardiol       Date:  1978-03       Impact factor: 2.778

8.  Mental stress-induced ischemia and all-cause mortality in patients with coronary artery disease: Results from the Psychophysiological Investigations of Myocardial Ischemia study.

Authors:  David S Sheps; Robert P McMahon; Lewis Becker; Robert M Carney; Kenneth E Freedland; Jerome D Cohen; David Sheffield; A David Goldberg; Mark W Ketterer; Carl J Pepine; James M Raczynski; Kathleen Light; David S Krantz; Peter H Stone; Genell L Knatterud; Peter G Kaufmann
Journal:  Circulation       Date:  2002-04-16       Impact factor: 29.690

9.  Mental stress--induced myocardial ischemia and cardiac events.

Authors:  W Jiang; M Babyak; D S Krantz; R A Waugh; R E Coleman; M M Hanson; D J Frid; S McNulty; J J Morris; C M O'Connor; J A Blumenthal
Journal:  JAMA       Date:  1996-06-05       Impact factor: 56.272

10.  Neurochemical approaches to the prevention of ventricular fibrillation.

Authors:  R L Verrier
Journal:  Fed Proc       Date:  1986-07
View more
  7 in total

1.  A polymorphism in the serotonin transporter gene moderates cardiovascular reactivity to psychosocial stress.

Authors:  Baldwin M Way; Shelley E Taylor
Journal:  Psychosom Med       Date:  2011-03-01       Impact factor: 4.312

2.  The association between panic disorder and coronary artery disease among primary care patients presenting with chest pain: an updated literature review.

Authors:  David A Katerndahl
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

3.  Effect of paroxetine on physiological response to stress and smoking.

Authors:  Michael Kotlyar; Mustafa al'Absi; Paul Thuras; John P Vuchetich; David E Adson; April L Nowack; Dorothy K Hatsukami
Journal:  Psychosom Med       Date:  2013-03-15       Impact factor: 4.312

4.  Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial.

Authors:  Wei Jiang; Eric J Velazquez; Maragatha Kuchibhatla; Zainab Samad; Stephen H Boyle; Cynthia Kuhn; Richard C Becker; Thomas L Ortel; Redford B Williams; Joseph G Rogers; Christopher O'Connor
Journal:  JAMA       Date:  2013-05-22       Impact factor: 56.272

5.  Effects of smoking and paroxetine on stress-induced craving and withdrawal symptoms.

Authors:  Michael Kotlyar; Hannah T Chau; Paul Thuras
Journal:  J Subst Use       Date:  2018-07-06

6.  A case study of a patient-centered reverse translational systems-based approach to understand adverse event profiles in drug development.

Authors:  Sarah Kim; Gezim Lahu; Majid Vakilynejad; Theodoros G Soldatos; David B Jackson; Lawrence J Lesko; Mirjam N Trame
Journal:  Clin Transl Sci       Date:  2022-01-11       Impact factor: 4.438

7.  The impact of escitalopram on vagally mediated cardiovascular function to stress and the moderating effects of vigorous physical activity: a randomized controlled treatment study in healthy participants.

Authors:  Camilla S Hanson; Tim Outhred; Andre R Brunoni; Gin S Malhi; Andrew H Kemp
Journal:  Front Physiol       Date:  2013-09-24       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.